Exelixis (EXEL) Cash Flow Statement

Click line-items for a historical chart and %

Consolidated net loss
Depreciation and amortization	456K
Stock-based compensation expense	14.74M
Impairment of assets due to restructuring
Gain on sale of business
Accretion of debt discount
Other	-1.14M
Other receivables
Prepaid expenses and other current assets	-851K
Other assets
Accounts payable and other accrued expenses	14.29M
Restructure liability
Other long-term liabilities	-493K
Deferred revenue	195.47M
Net cash used in operating activities	129.02M
Purchases of property and equipment	-1.08M
Proceeds from sale of property and equipment	112K
Proceeds on sale of business
Decrease in restricted cash and investments	2.65M
Proceeds from maturities of marketable securities
Proceeds from sale of marketable securities	17K
Purchases of marketable securities
Net cash used in investing activities	-143.51M
Proceeds from issuance of common stock
Proceeds from exercise of stock options and warrants
Proceeds from employee stock purchase plan
Proceeds from note payable and bank obligations
Principal payments on notes payable and bank obligations	0
Net cash provided by financing activities	2.69M
Net (decrease) increase in cash and cash equivalents	-11.81M
Cash and cash equivalents, at beginning of period	141.63M
Cash and cash equivalents, at end of period	129.83M

Entities mentioned with EXEL

View All Entities